Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Development of a novel risk stratification model for immune-related adverse events for patients with advanced melanoma and non-small cell lung cancer treated with immune checkpoint inhibitors.

View Full Paper
Ask AI
Bookmark
Share

Authors

YGYizhuo GaoATAndrew TranMGMehul Gupta

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gao et al. (2024) studied this question.

synapsesocial.com/papers/68e672c7b6db6435875fcb6ahttps://doi.org/10.1200/jco.2024.42.16_suppl.2649
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune-related adverse event prediction and influential factor identification.2024
  2. 2Early identification of patients at risk for moderate-to-severe immunotherapy-related adverse events following immune checkpoint inhibitor therapy.2026
  3. 3Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer2026 · 1 citations
  4. 4Development of an online prediction tool for immunotherapy-related adverse events in patients with advanced NSCLC based on machine learning and temporal validation2026
  5. 5Toxicity risk calculator for personalised prediction of irAEs in patients with solid tumours receiving ICIs, developed based on a clinical dataset and machine learning approaches.2026